DexCom (NASDAQ:DXCM) Surges on Strong Clinical Data and Financial Outlook

Font: Financial Modeling Prep  • Jun 08, 2026

• Raymond James increased its price target for DexCom (NASDAQ:DXCM) to $91.00, maintaining a "Strong Buy" rating.
• The Dexcom G7 CGM system demonstrated significant improvements in glycemic control for adults with Type 2 diabetes in the CONNECT trial.
• DexCom announced robust financial plans, including projected double-digit revenue growth and a $1 billion share buyback program.

DexCom (NASDAQ:DXCM) is a leading medical device company that designs and sells advanced continuous glucose monitoring (CGM) systems. These innovative devices are crucial for individuals, particularly those managing diabetes, enabling them to track their blood sugar levels in real-time. With a current market capitalization of approximately $29.57 billion, DexCom stands as a significant player in the rapidly evolving healthcare technology sector.

On June 8, 2026, the analyst firm Raymond James provided a positive update, increasing its price target for DexCom to $91.00, up from its previous target of $81.00. The firm also reiterated its "Strong Buy" rating on the stock. This optimistic revision came when the stock was trading at $76.62, indicating Raymond James' confidence in the company's future growth potential and investment outlook.

This positive outlook is further bolstered by recent clinical news. As highlighted by Zacks, DexCom announced successful results from its CONNECT trial. The study revealed that its Dexcom G7 CGM system significantly improves glycemic control for adults with Type 2 diabetes who do not use insulin. This key finding was prominently presented at the American Diabetes Association's 2026 Scientific Sessions, underscoring the system's efficacy in diabetes management.

The detailed trial data showcased specific benefits for users. Participants utilizing the G7 device experienced an average A1C reduction of 1.6%. A1C is a vital test that measures average blood sugar over several months. This reduction was 0.9% greater than the control group, which relied on traditional blood glucose monitoring. Furthermore, users of the Dexcom G7 spent approximately five extra hours daily within their target glucose range, demonstrating enhanced blood sugar stability.

In addition to the compelling clinical trial results, DexCom has outlined strong financial plans. As reported by Benzinga, the company projects robust double-digit revenue growth, signaling strong financial performance. Moreover, DexCom has authorized a substantial $1 billion share buyback program. A share buyback is a strategic move where a company repurchases its own stock, which can effectively increase the value of the remaining shares for investors and enhance shareholder value.